Community oncology practices can point to advantages such as care closer to home, greater affordability, and a more ...

The U.S. Food and Drug Administration (FDA) approved belzutifan (Welireg) in combination with lenvatinib (Lenvima) for adults ...

Joshua Brody, MD, highlights new DLBCL findings on frontline treatment, CAR T-cell therapy, and biomarkers from the 2026 Society of Hematologic Oncology Annual Meeting.

Explore how oncology partnerships are transforming utilization management through innovative approaches that improve patient care and streamline processes.

At WCLC 2026, three thoracic oncologists discuss first-line combinations, toxicity management, and subcutaneous amivantamab. Subcutaneous amivantamab cut infusion-related reactions to 13% to 16%, down ...

From administrative challenges to policy concerns, the challenges facing community oncology are “too many to count,” says Ted Okon, executive director of the Community Oncology Alliance. “If community ...

The U.S. Food and Drug Administration (FDA) approved lirafugratinib (Lyrfigtu) for adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma (CCA) harboring an ...

Frontline trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival (PFS) compared with pembrolizumab plus platinum-based chemotherapy in advanced or metastatic HER2-mutant ...

Adjuvant osimertinib (Tagrisso) continued to provide an overall survival (OS) benefit at eight years in patients with completely resected, EGFR-mutated stage IB–IIIA non-small cell lung cancer (NSCLC) ...

Significant progress against metastatic pancreatic cancer has been elusive. This explains why results from the RASolute 302 trial, which show that daraxonrasib doubled overall survival (OS) and ...